AU2001278981A1 - Prevention and treatment of sexual arousal disorders - Google Patents
Prevention and treatment of sexual arousal disordersInfo
- Publication number
- AU2001278981A1 AU2001278981A1 AU2001278981A AU7898101A AU2001278981A1 AU 2001278981 A1 AU2001278981 A1 AU 2001278981A1 AU 2001278981 A AU2001278981 A AU 2001278981A AU 7898101 A AU7898101 A AU 7898101A AU 2001278981 A1 AU2001278981 A1 AU 2001278981A1
- Authority
- AU
- Australia
- Prior art keywords
- prevention
- treatment
- sexual arousal
- arousal disorders
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22003100P | 2000-07-21 | 2000-07-21 | |
US60/220,031 | 2000-07-21 | ||
PCT/US2001/022970 WO2002007757A2 (en) | 2000-07-21 | 2001-07-19 | Prevention and treatment of sexual arousal disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001278981A1 true AU2001278981A1 (en) | 2002-02-05 |
Family
ID=22821763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001278981A Abandoned AU2001278981A1 (en) | 2000-07-21 | 2001-07-19 | Prevention and treatment of sexual arousal disorders |
Country Status (4)
Country | Link |
---|---|
US (2) | US6852323B2 (en) |
EP (1) | EP1365794A2 (en) |
AU (1) | AU2001278981A1 (en) |
WO (1) | WO2002007757A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001024809A1 (en) * | 1999-10-01 | 2001-04-12 | Duke University | A method of treating erectile dysfunction |
US20030027751A1 (en) * | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
US7437194B2 (en) * | 2003-10-31 | 2008-10-14 | Medtronic, Inc. | Stimulating the prostate gland |
CN107308162A (en) * | 2009-06-19 | 2017-11-03 | 泰华制药工业有限公司 | Multiple sclerosis is treated using laquinimod |
ES2564931T3 (en) * | 2009-07-30 | 2016-03-30 | Teva Pharmaceutical Industries Ltd. | Crohn's disease treatment with laquinimod |
EP3064206B1 (en) * | 2009-08-10 | 2019-03-20 | Active Biotech AB | Treatment of huntington's disease using laquinimod |
SG183515A1 (en) * | 2010-03-03 | 2012-10-30 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
KR20160129093A (en) * | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | Treatment of lupus nephritis using laquinimod |
JP5819328B2 (en) * | 2010-03-03 | 2015-11-24 | テバ ファーマシューティカル インダストリーズ リミティド | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
MX2014004420A (en) | 2011-10-12 | 2014-07-09 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod. |
AU2013214909A1 (en) | 2012-02-03 | 2014-09-18 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy |
TW201400117A (en) | 2012-06-05 | 2014-01-01 | Teva Pharma | Treatment of ocular inflammatory disease using laquinimod |
TW201410244A (en) | 2012-08-13 | 2014-03-16 | Teva Pharma | Laquinimod for treatment of GABA mediated disorders |
WO2016112049A1 (en) | 2015-01-06 | 2016-07-14 | Cardiovascular Biotherapeutics, Inc. | Angiogenic treatment of ischemic heart disease |
CA2976675A1 (en) * | 2015-02-16 | 2016-08-25 | Cardiovascular Biotherapeutics, Inc. | Therapeutic angiogenesis for treating erectile conditions |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5155214A (en) | 1984-03-05 | 1992-10-13 | The Salk Institute For Biological Studies | Basic fibroblast growth factor |
US5026839A (en) | 1985-12-17 | 1991-06-25 | Synergen, Inc | DNA encoding a basic fibroblast growth factor |
SE463851B (en) | 1988-09-02 | 1991-02-04 | Amsu Ltd | COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA |
US5188943A (en) | 1988-11-07 | 1993-02-23 | Synergen, Inc. | Method of producing high molecular weight human fibroblast growth factors |
US5130418A (en) | 1989-05-02 | 1992-07-14 | California Biotechnology Inc. | Method to stabilize basic fibroblast growth factor |
US5229500A (en) | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
US5180820A (en) | 1989-08-30 | 1993-01-19 | Barde Yves Alain | Brain-derived neurotrophic factor |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US5270053A (en) | 1990-04-03 | 1993-12-14 | Ciba-Geigy Corp. | Parenterally administerable liposome formulation comprising synthetic lipid |
US5217954A (en) | 1990-04-04 | 1993-06-08 | Scios Nova Inc. | Formulations for stabilizing fibroblast growth factor |
US5235043A (en) | 1990-04-06 | 1993-08-10 | Synergen, Inc. | Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins |
US5986070A (en) | 1990-04-06 | 1999-11-16 | Amgen Inc. | Production of biologically active NGF proteins |
JP2958076B2 (en) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same |
DK0550665T3 (en) * | 1990-09-25 | 1996-12-02 | Genentech Inc | New neurotrophic factor |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5206354A (en) | 1990-11-23 | 1993-04-27 | American Cyanamid Company | Dna sequence encoding active fragment of fibroblast growth factor, hbf-2 |
AU3062392A (en) * | 1991-11-04 | 1993-06-07 | Novo Nordisk A/S | Pdgf gel formulation |
DE4221256C2 (en) | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenic composition for topical use |
US5646181A (en) | 1992-07-02 | 1997-07-08 | Research Foundation Of State University Of New York | Method and compositions for treating impotence |
JPH06247842A (en) | 1993-02-23 | 1994-09-06 | Green Cross Corp:The | Production of liposome composition |
US5693531A (en) | 1993-11-24 | 1997-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vector systems for the generation of adeno-associated virus particles |
EP0758895B1 (en) * | 1994-04-22 | 2000-01-26 | Pentech Pharmaceuticals, Inc. | Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction |
US5607918A (en) | 1995-03-01 | 1997-03-04 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-B and DNA coding therefor |
US5741511A (en) | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
EP0825852B1 (en) | 1995-04-18 | 2004-07-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
US5830725A (en) | 1995-04-28 | 1998-11-03 | The Board Of Trustees For The Leland Stanford Junior University | Rapid, stable high-titre production of recombing retrovirus |
US6007838A (en) | 1995-06-07 | 1999-12-28 | The United States Of America As Represented By The Secretary Of The Army | Process for making liposome preparation |
DK1445322T4 (en) | 1995-06-15 | 2012-09-03 | Crucell Holland Bv | Packaging systems for human recombinant adenovirus for use in gene therapy |
JPH11510380A (en) | 1995-07-17 | 1999-09-14 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | p16 expression constructs and their application in cancer therapy |
EP0871512A1 (en) | 1995-12-22 | 1998-10-21 | Localmed, Inc. | Localized intravascular delivery of growth factors for promotion of angiogenesis |
US5736154A (en) | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
EP0914094A4 (en) | 1996-03-28 | 2000-03-01 | Univ Illinois | Materials and methods for making improved liposome compositions |
JPH10212241A (en) | 1996-05-27 | 1998-08-11 | Sumitomo Pharmaceut Co Ltd | Preparation stably containing bdnf |
US6133026A (en) | 1996-05-31 | 2000-10-17 | Sequus Pharmaceuticals, Inc. | Condensed plasmid-liposome complex for transfection |
US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
AU7983798A (en) | 1997-06-23 | 1999-01-04 | Sequus Pharmaceuticals, Inc. | Liposome-entrapped polynucleotide composition and method |
US6221646B1 (en) | 1997-07-31 | 2001-04-24 | Chiron Corporation | Materials and methods for simplified AAV production |
SE9703226D0 (en) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
US6197801B1 (en) | 1998-01-14 | 2001-03-06 | Usa Doctors Products, Inc. | Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
US5945117A (en) | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6031002A (en) | 1998-05-01 | 2000-02-29 | Michael Ebert | Method for enhancing female sexual response and a composition therefor |
US5891915A (en) | 1998-05-01 | 1999-04-06 | Wysor; Michael S. | Method for enhancing female sexual response and an ointment therefor |
US6056966A (en) | 1998-05-18 | 2000-05-02 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for treating impotence |
US5942545A (en) | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
US6706682B2 (en) * | 1999-01-21 | 2004-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of vascular endothelial growth factor in the treatment of erectile dysfunction |
FI991197A0 (en) | 1999-05-27 | 1999-05-27 | Mart Saarma | Neurotropic factors in the treatment of pelvic peripheral dysfunction |
US6436944B1 (en) * | 1999-09-30 | 2002-08-20 | Pfizer Inc. | Combination effective for the treatment of impotence |
WO2001024809A1 (en) * | 1999-10-01 | 2001-04-12 | Duke University | A method of treating erectile dysfunction |
AU2001250821A1 (en) * | 2000-03-10 | 2001-09-24 | Chiron Corporation | Methods and compositions for the treatment and prevention of erectile dysfunction |
-
2001
- 2001-07-19 WO PCT/US2001/022970 patent/WO2002007757A2/en active Search and Examination
- 2001-07-19 AU AU2001278981A patent/AU2001278981A1/en not_active Abandoned
- 2001-07-19 EP EP01957212A patent/EP1365794A2/en not_active Withdrawn
- 2001-07-19 US US09/909,544 patent/US6852323B2/en not_active Expired - Fee Related
-
2004
- 2004-03-22 US US10/806,515 patent/US7485311B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1365794A2 (en) | 2003-12-03 |
US20040180830A1 (en) | 2004-09-16 |
US6852323B2 (en) | 2005-02-08 |
US20020160951A1 (en) | 2002-10-31 |
WO2002007757A9 (en) | 2004-05-06 |
WO2002007757A2 (en) | 2002-01-31 |
US7485311B2 (en) | 2009-02-03 |
WO2002007757A3 (en) | 2003-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001078781A8 (en) | Methods for prevention and treatment of gastrointestinal disorders | |
GB0007193D0 (en) | Treatment of movrmrnt disorders | |
GB2368794B (en) | Prevention and treatment of amyloidogenic disease | |
HUP0201205A3 (en) | Prevention and treatment of amyloidogenic disease | |
AU2003290548A1 (en) | Prevention and treatment of synucleinopathic disease | |
AU2001247331A1 (en) | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | |
AU2001278981A1 (en) | Prevention and treatment of sexual arousal disorders | |
AU2001256855A1 (en) | Preparation for the prevention and treatment of ocular disorders | |
AU2001271887A1 (en) | Methods for diagnosis and treatment of psychiatric disorders | |
AUPQ622600A0 (en) | Treatment and/or prevention of ocular pain | |
AU5908300A (en) | Prevention and treatment of amyloid-associated disorders | |
AU4663100A (en) | Treatment of female arousal disorder | |
AU2002340465A1 (en) | Cyclo(prolyl-glycine) and methods of use to treat neural disorders | |
AU7601400A (en) | Treatment and prevention of hepatic disorders | |
GB0128674D0 (en) | Treatment of sleep disorders and the like | |
AU2001251306A1 (en) | Treatment of sleep disorders with hypocretin-1 | |
AU2002228652A1 (en) | Treatment of disorders using polyethylenimine diazeniumdiolate | |
AU2001269785A1 (en) | Method of treatment of obesity and paralyzed muscle and ergogenic aids | |
GB2360453B (en) | Treatment of skin conditions | |
PL362980A1 (en) | Treatment of sexual dysfunction | |
AU2001267165A1 (en) | Prevention and treatment of mycoplasma-associated diseases | |
IL152782A0 (en) | S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders | |
AU2002222125A1 (en) | Prevention and treatment of tachyphylactic response | |
IL142102A0 (en) | Zinc-sensing receptor and methods of treatment of disorders associated herewith | |
AU2001239005A1 (en) | Treatment and/or prevention of ocular pain |